Insight

Giuseppe Procopio: Current status of adiuvant immunotherapy in RCC

Photo: ilgiorno.it

Jun 13, 2025, 09:43

Giuseppe Procopio: Current status of adiuvant immunotherapy in RCC

Giuseppe Procopio, Head of the Genitourinary Unit at Fondazione Istituto Nazionale Tumori, Milan, shared a post on X:

“Current status of adiuvant immunotherapy in RCC: a Delphi study coordinated by Bernard Escudier.”

Title: Current Status of Adjuvant Immunotherapy and Relapse Management in Renal Cell Carcinoma: Insights from a European Delphi study

Authors: Viktor Grünwald, Axel Bex, Sylvie Rottey, Cristina Suárez, Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, Mário Fontes-Sousa, Manuela Schmidinger, Aristotelis Bamias, Marine Gross-Goupil, Camillo Porta, Philippe Barthélémy, Bernard Escudier, Laurence Albiges

Read the Full Article.

Aristotelis Bamias Axel Bex Bernard Escudier Bohuslav Melichar Camillo Porta cancer Cristina Suárez Giuseppe Procopio Guillermo Velasco immunotherapy Jens Bedke Laurence Albiges Lisa Pickering Manuela Schmidinger Marine Gross-Goupil Mário Fontes-Sousa OncoDaily Oncology Philippe Barthélémy Sylvie Rottey Viktor Grünwald

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening